The evaluation of acute and subchronic toxicities of An Phu Khang capsules in experimental animals

Ha Thi Yen, Tran Thanh Tung, Dang Thi Thu Hien

Nội dung chính của bài viết

Tóm tắt

The purpose of this research was to evaluate the acute and subchronic toxicities of An Phu Khang capsules through oral administration in experimental animals. The acute toxicity was determined by the method of Litchfield Wilcoxon in Swiss mice. The subchronic toxicity was evaluated by the recommendation of WHO in Wistar rats at these doses of 0.54 g/kg b.w/day (equal to recommended human dose) and 1.62 g/kg b.w/day (3 times as high as recommended human dose) in 4 consecutive weeks. As a result, An Phu Khang capsules at the highest dose used for mice (36.29 g/kg b.w) did not show acute toxicity in mice. In terms of the subchronic toxicity test, after oral administration of An Phu Khang capsules, hematological parameters, hepato-renal functions, and microscopic images of liver and kidney at both doses were unchanged compared with the control group. In conclusion, An Phu Khang with both doses 0.54 g/kg b.w/day and 1.62 g/kg b.w/day did not produce acute and subchronic toxicities in Swiss mice and Wistar rats.

Chi tiết bài viết

Tài liệu tham khảo

1. Ogbonnia S, Adekunle AA, Bosa MK, Enwuru VN. Evaluation of acute and subacute toxicity of Alstonia congensis Engler (Apocynaceae) bark and Xylopia aethiopica (Dunal) A. Rich (Annonaceae) fruits mixtures used in the treatment of diabetes. Afr J Biotechnol. 2008;7(6). doi:10.4314/ajb.v7i6.58507.
2. World Health Organization. WHO Global Report on Traditionnal and Complementary Medicin. World Health Organization; 2010. Accessed September 14, 2021.
3. Alhaji Saganuwan S. Toxicity studies of drugs and chemicals in animals: An overview. Bulg J Vet Med. 2017;20:291-318. doi:10.15547/bjvm.983.
4. Jong WH, Carraway J, Re G. In vivo and in vitro testing for the biological safety evaluation of biomaterials and medical devices. Biocompat Perform Med Devices. Published online October 1, 2012;120-158. doi:10.1016/B978-0-85709-070-6.50007-9.
5. Zhao Y-L, Su M, Shang J-H, et al. Acute and Chronic Toxicity of Indole Alkaloids from Leaves of Alstonia scholaris (L.) R. Br. in Mice and Rats. Nat Prod Bioprospecting. 2020;10(2):77-88. doi:10.1007/s13659-020-00237-1.
6. Loan Pham T, Huy Nguyen V, Tam Tien Ha T, Le Thu Hoang T, NghiaPhan C, Quyen Nguyen T. Evaluation of Acute Toxicity and Semi-chronic Toxicity of Extract from Celastrus hindsii Benth. Pak J Biol Sci PJBS. 2020;23(8):1096-1102. doi:10.3923/pjbs.2020.1096.1102.
7. Nguyen H-YT, Vo B-HT, Nguyen L-TH, et al. Extracts of Crinum latifolium inhibit the cell viability of mouse lymphoma cell line EL4 and induce activation of anti-tumour activity of macrophages in vitro. J Ethnopharmacol. 2013;149(1):75-83. doi:10.1016/j.jep.2013.06.002.
8. Zhang S, Chen C, Lu W, Wei L. Phytochemistry, pharmacology, and clinical use of Panax notoginseng flowers buds. Phytother Res PTR. 2018;32(11):2155-2163. doi:10.1002/ptr.6167.
9. Pirzada AM, Ali HH, Naeem M, Latif M, Bukhari AH, Tanveer A. Cyperus rotundus L.: Traditional uses, phytochemistry, and pharmacological activities. J Ethnopharmacol. 2015;174:540-560. doi:10.1016/j.jep.2015.08.012.
10. OECD. Guidance Document on Acute Oral Toxicity Testing. OECD. 2002. doi:10.1787/9789264078413-en.
11. World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. Published online 2007;105.
12. Litchfield JT, Wilcoxon F. A Simplified Method of Evaluating Dose-Effect Experiments. J Pharmacol Exp Ther. 1949;96(2):99-113.
13. Saad B, Azaizeh H, Abu-Hijleh G, Said O. Safety of traditional arab herbal medicine. Evid-Based Complement Altern Med ECAM. 2006;3(4):433-439. doi:10.1093/ecam/nel058.
14. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci. 2002;23(3):136-139. doi:10.1016/S0165-6147(00)01972-6.
15. Cosyns J-P. Aristolochic acid and “Chinese herbs nephropathy”: a review of the evidence to date. Drug Saf. 2003;26(1):33-48. doi:10.2165/00002018-200326010-00004.
16. Sk R. Preclinical safety assessment: current gaps, challenges, and approaches in identifying translatable biomarkers of drug-induced liver injury. Clin Lab Med. 2011;31(1). doi:10.1016/j.cll.2010.10.004.
17. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008; 245(3):194-205. doi:10.1016/j.tox.2007.11.021.